Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Clinical trial NCT06317662 · RECRUITING
Trial details
- NCT number
- NCT06317662
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-05
- Primary completion
- 2028-12-31
- Enrollment
- 153
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.